Jindike: After the production of the company’s quadrivalent influenza vaccine products, it must be submitted to the Central Inspection Institute for batch issuance and approval before it can be sold on the market.

Every time the AI ​​Express is sent, some investors ask questions on the investor interactive platform: Happy New Year! With 98 batches approved this year, the company’s net profit in the fourth quarter was less than 70 million, even far lower than that in the third quarter. It is not an exaggeration to describe “there will be monsters when things go wrong” in one sentence. May I ask the profit in the fourth quarter Is the reason for so few intentional or is there something else hidden?

　　Jindick(688670.SH) said on the investor interactive platform on February 11 that 1. After the company’s quadrivalent influenza vaccine products are produced, they must be submitted to the Central Inspection Institute for batch issuance. The number of batches issued is the number of products available for sale, and does not represent the sales volume of the company. 2. The company’s 2021 annualperformancePlease pay attention to the 2021 annual report disclosed by the company at that time.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 92

Original title: Jindike: After the company’s quadrivalent influenza vaccine products are produced, they must be submitted to the Central Inspection Institute for batch issuance, and can only be marketed after the batch issuance is qualified.